Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome

被引:42
|
作者
Kaushik, Shalini V. [1 ,2 ]
Plaisance, Eric P. [2 ,3 ]
Kim, Teayoun [1 ,2 ]
Huang, Edmond Y. [1 ,2 ]
Mahurin, A. Jack [5 ]
Grandjean, Peter W. [2 ,4 ]
Mathews, Suresh T. [1 ,2 ]
机构
[1] Auburn Univ, Dept Nutr & Food Sci, Auburn, AL 36849 USA
[2] Auburn Univ, Boshell Diabet & Metab Dis Res Program, Auburn, AL 36849 USA
[3] Auburn Univ, Dept Anat Physiol & Pharmacol, Auburn, AL 36849 USA
[4] Auburn Univ, Dept Kinesiol, Auburn, AL 36849 USA
[5] Baptist Family Med Residency Program, Montgomery, AL 36116 USA
关键词
fetuin-A; niacin; Niaspan; alpha 2-HS glycoprotein; metabolic syndrome; triglycerides; MOLECULAR-WEIGHT ADIPONECTIN; RECEPTOR TYROSINE KINASE; INSULIN-RESISTANCE; NICOTINIC-ACID; INFLAMMATORY MARKERS; MEDIA THICKNESS; PLASMA; ASSOCIATION; INHIBITOR; GENE;
D O I
10.1002/dmrr.967
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Fetuin-A, a liver-secreted phosphoprotein and physiological inhibitor of insulin receptor tyrosine kinase, is associated with insulin resistance, metabolic syndrome (MetS), and an increased risk for type 2 diabetes. However, studies on the modulation of circulating levels of fetuin-A are limited. The goal of this study was to determine the effect of niacin administration on serum total- and phosphorylated fetuin-A (phosphofetuin-A) concentrations in individuals with MetS and correlate with changes in serum lipids, insulin sensitivity, and markers of inflammation. Methods Fifteen sedentary, obese, male participants, who met the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria for MetS, were treated with extended-release niacin (Niaspan) for 6 weeks. Blood samples were obtained before and after treatment with niacin. Results Serum fetuin-A and phosphofetuin-A concentrations were decreased following niacin administration (p < 0.005). Changes in fetuin-A concentrations were correlated with changes in triglyceride (r = 0.62, p = 0.01) and C-reactive protein (CRP) concentrations (r = 0.58, p, < 0.05) after nacin treatment. Changes in high-density lipoproteins (HDL)-cholesterol following niacin intervention were negatively correlated with changes in serum fetuin-A (p < 0.05) and phosphofetuin-A concentrations (p < 0.05). Serum cortisol levels were significantly elevated after niacin administration. Conclusions Niacin treatment lowers serum total- and phosphofetuin-A concentrations in individuals with MetS, and these changes correlate with the beneficial changes in serum lipids. Because niacin is known to induce insulin resistance, these findings suggest that fetuin-A may not be a mediator of niacin-induced insulin resistance but it may blunt the insulin resistance induced by niacin by decreasing its circulating concentrations. Copyright (c) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:427 / 434
页数:8
相关论文
共 50 条
  • [31] Fetuin-a to adiponectin ratio is a sensitive indicator for evaluating metabolic syndrome in the elderly
    Zhongwei Zhou
    Mingzhong Sun
    Hao Jin
    Hongmei Chen
    Huixiang Ju
    Lipids in Health and Disease, 19
  • [32] Blood Pressure-Lowering Effects of Extended-Release Niacin Alone and Extended-Release Niacin/Laropiprant Combination: A Post Hoc Analysis of a 24-Week, Placebo-Controlled Trial in Dyslipidemic Patients
    Bays, Harold E.
    Maccubbin, Darbie
    Meehan, Alan G.
    Kuznetsova, Olga
    Mitchel, Yale B.
    Paolini, John F.
    CLINICAL THERAPEUTICS, 2009, 31 (01) : 115 - 122
  • [33] Clinical utility of extended-release niacin: update and summary
    Cheung, Rebecca J.
    Ito, Matthew K.
    FUTURE CARDIOLOGY, 2005, 1 (05) : 571 - 578
  • [34] Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety
    Yadav, Rahul
    France, Michael
    Younis, Naveed
    Hama, Salam
    Ammori, Basil J.
    Kwok, See
    Soran, Handrean
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (09) : 1345 - 1362
  • [35] Serum Fetuin-A levels, insulin resistance and oxidative stress in women with polycystic ovary syndrome
    Enli, Yasar
    Fenkci, Semin Melahat
    Fenkci, Veysel
    Oztekin, Ozer
    GYNECOLOGICAL ENDOCRINOLOGY, 2013, 29 (12) : 1036 - 1039
  • [36] Clinical and Biochemical Parameters in Relation to Serum Fetuin-A Levels in Overweight and Obese with and without Metabolic Syndrome in the Northeastern States of Indian Population
    Eswar, Sruti
    Rajagopalan, Balaji
    Ete, Kenyi
    Gattem, Srinivasa Nageswara Rao
    JMA JOURNAL, 2024,
  • [37] Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
    Landray, Martin J.
    Haynes, Richard
    Hopewell, Jemma C.
    Parish, Sarah
    Aung, Theingi
    Tomson, Joseph
    Wallendszus, Karl
    Craig, Martin
    Jiang, Lixin
    Collins, Rory
    Armitage, Jane
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) : 203 - 212
  • [38] Fetuin-A serum levels in patients with aortic aneurysms of Marfan syndrome and atherosclerosis
    Szeberin, Zoltan
    Fehervari, Matyas
    Krepuska, Miklos
    Apor, Astrid
    Rimely, Endre
    Sarkadi, Hunor
    Biro, Gabor
    Sotonyi, Peter
    Szeplaki, Gabor
    Szabolcs, Zoltan
    Prohaszka, Zoltan
    Kalabay, Laszlo
    Acsady, Gyoergy
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2011, 41 (02) : 176 - 182
  • [39] Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease
    Maccubbin, Dorbie
    Koren, Michael J.
    Davidson, Michael
    Gavish, Dov
    Pasternak, Richard C.
    Macdonell, Geraldine
    Mallick, Madhuja
    Sisk, Christine McCrary
    Paolini, John F.
    Mitchel, Yale
    AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104 (01) : 74 - 81
  • [40] Relationship of serum Fetuin-A with metabolic and vascular parameters in patients with prediabetes and type 2 diabetes mellitus
    Karamfilova, Vera
    Nedeva, Iveta
    Gatev, Tsvetan
    Gateva, Antoaneta
    Assyov, Yavor
    Gerganova, Antonina
    Popov, Dobrin
    Velikova, Tsvetelina
    Kamenov, Zdravko
    PHARMACIA, 2023, 70 (04) : 1455 - 1461